User profiles for Tobias Herold
 | Tobias HeroldAttending physician and research group leader, University of Munich Verified email at med.uni-muenchen.de Cited by 7338 |
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
T Herold, V Jurinovic, C Arnreich, BJ Lipworth… - Journal of Allergy and …, 2020 - Elsevier
… Author links open overlay panel Tobias Herold MD a b c d e ∗ , Vindi Jurinovic PhD a d f
∗ , Chiara Arnreich a d , Brian J. Lipworth MD g , Johannes C. Hellmuth MD a h , Michael von …
∗ , Chiara Arnreich a d , Brian J. Lipworth MD g , Johannes C. Hellmuth MD a h , Michael von …
A 17-gene stemness score for rapid determination of risk in acute leukaemia
…, AC Schuh, KW Yee, L Bullinger, T Herold… - Nature, 2016 - nature.com
Refractoriness to induction chemotherapy and relapse after achievement of remission are
the main obstacles to cure in acute myeloid leukaemia (AML) 1 . After standard induction …
the main obstacles to cure in acute myeloid leukaemia (AML) 1 . After standard induction …
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
KH Metzeler, T Herold… - Blood, The Journal …, 2016 - ashpublications.org
The clinical and prognostic relevance of many recently identified driver gene mutations in
adult acute myeloid leukemia (AML) is poorly defined. We sequenced the coding regions or …
adult acute myeloid leukemia (AML) is poorly defined. We sequenced the coding regions or …
[HTML][HTML] COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL …
…, M Foglietta, M Gentile, Y Herishanu, T Herold… - Leukemia, 2020 - nature.com
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by
immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe …
immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe …
[HTML][HTML] Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
T Herold, M Rothenberg-Thurley, VV Grunwald… - Leukemia, 2020 - nature.com
The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification
of acute myeloid leukemia have been widely adopted, but have not yet been validated in …
of acute myeloid leukemia have been widely adopted, but have not yet been validated in …
Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients
T Herold, V Jurinovic, C Arnreich, JC Hellmuth… - MedRxiv, 2020 - medrxiv.org
The pandemic Coronavirus-disease 19 (COVID-19) is characterized by a heterogeneous
clinical course. While most patients experience only mild symptoms, a relevant proportion …
clinical course. While most patients experience only mild symptoms, a relevant proportion …
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
…, W Fiedler, C Kellner, E Beltrán, T Herold… - Nature …, 2023 - nature.com
Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option
for individuals with B cell malignancies but have yet to achieve success in treating acute …
for individuals with B cell malignancies but have yet to achieve success in treating acute …
GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia
…, B Tizazu, J Sturm, T Benthaus, T Herold… - Blood, The Journal …, 2012 - ashpublications.org
Cytogenetically normal acute myeloid leukemia (CN-AML) with biallelic CEBPA gene mutations
(biCEPBA) represents a distinct disease entity with a favorable clinical outcome. So far, …
(biCEPBA) represents a distinct disease entity with a favorable clinical outcome. So far, …
GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo
Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy,
which is initiated and driven by a rare fraction of leukemia stem cells (LSCs). Despite the …
which is initiated and driven by a rare fraction of leukemia stem cells (LSCs). Despite the …
[PDF][PDF] RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells
Since acute myeloid leukemia (AML) is characterized by the blockade of hematopoietic
differentiation and cell death, we interrogated RIPK3 signaling in AML development. Genetic loss …
differentiation and cell death, we interrogated RIPK3 signaling in AML development. Genetic loss …